Advanced Accelerator Applications to Build Targeted Radioligand Therapy Production Facility in Indianapolis; - Site to produce targeted radioligand drugs used in the treatment of cancer
Jun 30, 2020 - PR Newswire
PR Newswire
Advanced Accelerator Applications S.A.(AAA), a Novartis company, today announced it has executed a sales and purchase agreement for land on which a 50,000 square foot targeted Radioligand Therapy (RLT) manufacturing plant will be built. The new facility will be located within the Purdue Research Park, near the Indianapolis International Airport, with completion and initial operations anticipated in 2023.
The facility will significantly expand AAA's manufacturing ...
Sign up today to gain access to 5 free articles a month from over 200 top subscription outlets.
Are you ready to take your business development to the next level with RelSci Professional?
Nurture your network with daily alerts that notify you when your relationships make news
Map your relationships to any target or prospect to identify a warm introduction
Access unlimited deep dossiers on over 8 million decision makers
Best of all, you can try out all these powerful business development tools absolutely free for 30 days!
Check out News Home to stay on top of the people and organizations you care most about.
